We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Modified Adenovirus Vector Used for Cancer Gene Therapy

By LabMedica International staff writers
Posted on 15 Feb 2018
Print article
Image: An adenovirus without and with a novel protein shield. The adenovirus (left) was camouflaged from the immune system by the protective coat (right) (Photo courtesy of the University of Zurich).
Image: An adenovirus without and with a novel protein shield. The adenovirus (left) was camouflaged from the immune system by the protective coat (right) (Photo courtesy of the University of Zurich).
A team of medical virologists has modified the commonly used adenovirus vector to both avoid clearance by the immune system and liver and to specifically target and invade tumor cells.

The clinical application of most systemic viral gene therapies has been limited by the efficient neutralization of the viruses by the immune system and their rapid elimination by the liver. Furthermore, adenovirus has been of little use in the realm of cancer therapy, as this virus does not normally invade tumor cells.

Investigators at the University of Zurich (Switzerland) developed a "work-around" to empower an adenovirus vector for use as a carrier for cancer gene therapy. They engineered a high-affinity protein coat that shielded the most commonly used vector in clinical gene therapy, human adenovirus type 5. Using electron microscopy and crystallography they demonstrated a massive coverage of the virion surface through the hexon-shielding scFv fragment, which was trimerized to exploit the hexon symmetry and gain avidity. In addition, the shield reduced virion clearance in the liver.

When the shielded particles were equipped with adaptor proteins, the virions delivered their payload genes into human cancer cells expressing the HER2 or EGFR surface proteins.

The investigators further reported in the January 31, 2018, online edition of the journal Nature Communications that the combination of shield and adapter also increased viral gene delivery to xenografted tumors in vivo, reduced liver off-targeting, and minimized immune neutralization.

"With this gene shuttle, we have opened up many avenues to treat aggressive cancers in the future, since we can make the body itself produce a whole cocktail of therapeutics directly in the tumor," said senior author Dr. Andreas Plueckthun, professor of biochemistry at the University of Zurich.

Related Links:
University of Zurich

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.